Login / Signup

Refractory thrombotic thrombocytopenic purpura related to checkpoint inhibitor immunotherapy.

Moira LancelotMaureen J MillerJohn RobackSean R Stowell
Published in: Transfusion (2020)
This case illustrates not only that TTP may be a potential complication of checkpoint inhibitor therapy, but also that TTP developing in this setting may result in an unpredictable response to commonly employed TTP treatment modalities. Ultimately, checkpoint inhibitor-related TTP may require distinct management approaches and prognostic considerations.
Keyphrases
  • dna damage
  • cell cycle
  • stem cells
  • stress induced
  • cell therapy
  • smoking cessation